TRACON Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with
|Company Contact:||Investor Contact:|
|Patricia Bitar||Andrew McDonald|
|Chief Financial Officer||LifeSci Advisors LLC|
|(858) 550‐0780 ext. 223||646-597-6987|
Source: TRACON Pharmaceuticals, Inc.